Study Reveals Health Benefits of Mounjaro Reversed When Jabs Are Stopped
A recent study highlights the significant health benefits gained from Mounjaro, a popular weight loss injection, can be quickly reversed after discontinuation. Mounjaro, which contains the active ingredient tirzepatide, has earned a reputation for its effectiveness, reportedly aiding individuals in losing up to 25% of their body weight in as little as 18 months.
Impact of Stopping Mounjaro Treatment
The findings, published in the journal *Jama Internal Medicine*, reveal alarming statistics. Among a sample of 308 participants who benefited from weight reduction and various health improvements while using tirzepatide, a staggering 82% regained 25% or more of their weight after stopping the medication. Not only did they regain weight, but they also experienced declines in blood pressure and “bad” cholesterol levels, which had improved during treatment.
Expert Insights on Weight Regain
The research team associated with the Surmount-4 study underscored the link between weight regain and the reversal of health benefits. They stated, “Higher weight regain on withdrawal of tirzepatide was associated with a greater reversal of improvements in cardiometabolic parameters achieved with tirzepatide treatment.” This reinforces the importance of ongoing obesity treatment for those living with obesity.
Guidance from Health Authorities
The National Institute for Health and Care Excellence (Nice) has previously warned about the harsh reality of weight regain after ceasing weight loss injections. Their guidance stresses that many individuals face challenges if not sufficiently supported post-treatment. Research published in *BMC Medicine* outlined the broader pattern of weight regain experienced by patients after completing their medication course.
Strategies for Long-Term Success
Nice advocates for building sustainable weight management strategies. They recommend:
- Establishing long-term behavioral habits.
- Utilizing self-monitoring tools.
- Leveraging support from online communities, family interventions, and local activities.
Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, emphasized that “successful weight management doesn’t end when medication stops.” He urged for structured support during the critical transition after treatment, indicating that this is vital for maintaining positive health changes.
This study serves as a crucial reminder of the need for continuous care within weight management programs. The call for a more preventive health system aligns with the NHS’s 10-Year Plan, aiming to transition from reactive care to proactive health solutions.
